After a successful overseas festival in Sydney, Australia, SXSW will head to London in 2025. Photo courtesy of SXSW

Get ready to see triple in 2025: South by Southwest (SXSW) is heading across the pond for its first-ever conference in London in June 2025.

According to a press release, the new European festival and conference will aim to showcase London's "status as a global meeting place." Much like the original Austin festival, SXW London will occupy dozens of galleries, clubs, and other event venues throughout Shoreditch – located in east London – for its conference sessions, exhibitions, film screenings, activations, music showcases, and much more.

"SXSW London will build on Austin's incredible legacy, presenting an event that underpins why SXSW is the go-to destination for professionals and creatives seeking meaningful connections, unexpected experiences and ideas that can help shape the world," said SXSW London managing director Randel Bryan in the release.

SXSW held its first overseas festival in Sydney, Australia in 2023; The festival counted more than 287,000 attendees, encouraging leadership and organizers to expand further outside of the U.S.

London was a clear-cut choice thanks to the city's diversity, economy, and innovation. The release said the United Kingdom's cultural and creative industries alone generate £125 billion (over $156 billion), with more than half of that revenue coming from London.

Sadiq Kha, the mayor of London, said in a statement that he was inspired to facilitate a partnership with SXSW after visiting Austin during the 2018 festival.

"This is a historic opportunity for London to once again bring the world’s most exciting talent together as part of our mission to build a better and more prosperous London for everyone," Kha said.

While official festival dates are still under wraps, the release says badges are expected to go on sale in October 2024. More information about SXSW London 2025 can be found on sxswlondon.com.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”